Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies — Xin Hui S Chan (2022) | RDL Network
Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies
British Journal of Clinical Pharmacology 89(3): 1176-1186
Article 2022 English
Authors
XC
Xin Hui S Chan
PC
Palang Chotsiri
RC
Rebecca A. Capel
Abstract
1 min read
Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized.
Xin Hui S Chan, Ilsa L. Haeusler, Yan Naung Win, James Pike, Borimas Hanboonkunupakarn, Maryam Hanafiah, Sue J. Lee, Abdoulaye Djimdé, Caterina Fanello, Jean‐René Kiechel, Marcus Lacerda, Bernhards Ogutu, Marie Onyamboko, André M. Siqueira, Elizabeth A. Ashley, Walter RJ Taylor, Sir Nicholas White
Joel Tärning, Palang Chotsiri, Vincent Jullien, Marcus J. Rijken, Martin Bergstrand, Mireille Cammas, Rose McGready, Pratap Singhasivanon, Nicholas Day, Sir Nicholas White, François Nosten, Niklas Lindegårdh
Marcus J. Rijken, Rose McGready, Vincent Jullien, Joel Tärning, Niklas Lindegårdh, Aung Pyae Phyo, Aye Kyi Win, Poe Hsi, Mireille Cammas, Pratap Singhasivanon, Sir Nicholas White, François Nosten
Discussion(0)
No comments yet. Be the first to comment.